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Anesthetic management of patients undergoing pulmonary vein isolation for atrial fibril-
lation has specific requirements. The feasibility of non-invasive ventilation (NIV) added to
deep sedation procedure was evaluated.
Seventy-two patients who underwent ablation procedure were retrospectively revised,
performed with (57%) or without (43%) application of NIV (Respironic® latex-free total face
mask connected to Garbin ventilator-Linde Inc.) during deep sedation (Midazolam 0.01
e0.02 mg/kg, fentanyl 2.5e5 mg/kg and propofol: bolus dose 1e1.5 mg/kg, maintenance 2
e4 mg/kg/h).
In the two groups (NIV vs deep sedation), differences were detected in intraprocedural
(pH 7.37 ± 0.05 vs 7.32 ± 0.05, p ¼ 0.001; PaO2 117.10 ± 27.25 vs 148.17 ± 45.29, p ¼ 0.004;
PaCO2 43.37 ± 6.91 vs 49.33 ± 7.34, p ¼ 0.002) and in percentage variation with respect to
basal values (pH 0.52 ± 0.83 vs 1.44 ± 0.87, p ¼ 0.002; PaCO2 7.21 ± 15.55 vs 34.91 ± 25.76,
p ¼ 0.001) of arterial blood gas parameters. Two episodes of respiratory complications,
treated with application of NIV, were reported in deep sedation procedure. Endotracheal
intubation was not necessary in any case. Adverse events related to electrophysiological
procedures and recurrence of atrial fibrillation were recorded, respectively, in 36% and 29%
of cases.
NIV proved to be feasible in this context and maintained better respiratory homeostasis
and better arterial blood gas balance when added to deep sedation.
Copyright © 2015, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
The delicate catheter ablation of atrial fibrillation (AF) involves




mons.org/licenses/by-ncless than 1 in 2000 [1e3]. Patients undergoing catheter ablation
for AF are required to liemotionless on the procedure table for
several hours, and repeated stimuli from ablation are some-
times painful. For these reasons, patients are treated with
deep sedation or general anesthesia. The safety of deepa Moruzzi, 1, 56124 Pisa, Italy. Tel.: þ39 050 315 2216; fax: þ39 050
and hosting by Elsevier B.V. This is an open access article under
-nd/4.0/).
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high-frequency jet ventilation during general anesthesia has
also proved to be a safe technique [5].
Aid for anesthetic management in these setting can be
non-invasive ventilation (NIV), first used in acute respiratory
failure [6], sometimes during sedation [7], subsequently used
outside of the intensive care unit [8] and in cardio-surgical
procedures [9e12].
The aim of our study was to evaluate the usefulness of NIV
during sedation in catheter ablation of use AF instead of atrial
fibrillation compared to deep sedation.Materials and methods
Study design and patient selection
In the study period (24 months), conducted in a single high-
volume electrophysiology procedure center, consecutive
patients undergoing catheter ablation for paroxysmal/
persistent atrial fibrillation [1] were retrospectively revised
(Fig. 1).
All patients provided informed consent to participate in
the study. Exclusion criteria for the procedure were left ejec-
tion fraction less than 40%, moderate-to-severe mitral valve
disease, severe heart failure (New York Heart Association
functional class III or IV), expected surgery for structural heart
disease, secondary AF (due to cardiac surgery, infection or
hyperthyroidism), severe COPD with concomitant respiratory
insufficiency (PaO2 < 60 mmHg), presence of inducible
myocardial ischemia or other acute illness underway, or
contraindications to anesthesia. Complications and recur-
rence of AF occurring within 48 h of the electrophysiological
procedure were also examined.Fig. 1 e Patients flow diAnesthesiological management
Perioperative anesthesia visits and sedation procedures
were performed according to SIAARTI (Societa Italiana di
Anestesia Analgesia Rianimazione e Terapia Intensiva)
guidelines [13,14], including pulmonary function tests in the
anesthetic assessment. Routine monitoring (electrocardi-
ography, pulse oximetry, invasive arterial pressure, seriate
arterial blood gas analysis and apnea monitor) were per-
formed. Sedation and NIV were performed after trans-septal
puncture in order to rule out left-sided emboli through
neurologic assessment.
Midazolam 0.01e0.02 mg/kg IV was administered imme-
diately before monitoring, fentanyl (2.5e5 mg/kg) was admin-
istered as analgesic and sedation was performed by propofol
infusion (bolus dose 1e1.5 mg/kg, maintenance 2e4 mg/kg/h).
The infusion rate was carefully titrated to achieve a target
sedation level of a Ramsay sedation scale [15] of 2e3. Mean
arterial pressure was maintained above 75 mmHg during the
entire procedure.
During deep sedation, the patients were breathing spon-
taneously and were given supplemental oxygen (FiO2
80e100%) to maintain the oxygen saturation level above 92%.
In patients undergoing NIV ventilation the procedure was
performed with a Respironic® latex-free total face mask con-
nected to Garbin ventilator (Linde Inc., Herrsching, Germany)
in Spontaneous/Temporized mode applying incorporated al-
gorithms to improve patient-ventilator synchrony by adjust-
ing to changing breathing patterns and dynamic leaks. I-PAP,
E-PAP and respiratory rate were modified according to the
clinical response, tolerance of the patient to obtaining exhaled
tidal volume of 6e8ml/kg; FiO2 requirementwas 40% or less to
maintain oxygen saturation above 92%. The ventilator set-
tings were adjusted on the basis of pulse oximetry and serial
measurement of arterial blood gases.agram of the study.
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discontinued or at the end of the catheter ablation procedure.
At the end of the procedure, patients were transferred, ac-
cording to hospital protocol, to the intensive care unit for
monitoring.Catheter ablation
Oral anticoagulation with stable international normalized
ratio (INR) superior to 2.0 was ensured for at least 3 weeks
before ablation. Transesophageal echocardiography was per-
formed within 24 h before the procedure, to rule out the
presence of left atrial thrombi. Local anesthesia (lidocaine 1%)
was administered subcutaneously at the femoral venous ac-
cess site. After septal puncture of interatrial septum, intra-
venous heparin was administered according to institutional
standards. The ablation procedure was guided by electro-
anatomical mapping (NavX, St. Jude Medical Inc., Minneap-
olis, MN, USA or CARTO-3mapping system, BiosenseWebster,Table 1 e Clinical characteristics of patients.
Characteristic All patients
n ¼ 72
Age (years) 62 ± 10
Male gender, n (%) 58 (81)
Hypertension, n (%) 36 (50)
Diabetes, n (%) 9 (13)
Smoke exposure, n (%) 32 (44)
Current smoke exposure, n (%) 14 (31)
ASA I, n (%) 2 (3)
ASA II, n (%) 70 (97)
NYHA functional class I, n (%) 38 (53)
NYHA functional class II, n (%) 34 (47)
Weight (Kg) 82 ± 15
Height (cm) 171 ± 22
Body mass index 27 ± 4
Left ventricular ejection fraction, n (%) 57 ± 8
FVC (liters) 4.33 ± 1.24
FEV1 (liters) 3.18 ± 0.88
Time of catheter ablation procedure, min 262 ± 43
Radiofrequency energy ablation catheter, n (%) 59 (82)
Cryoablation balloon catheter, n (%) 13 (18)
Time of anesthesia, min 162 ± 51
Time of NIV, min N/A
Basal pH 7.42 ± 0.03
Basal PaO2 (mmHg) 85.04 ± 10.53
Basal PaCO2 (mmHg) 39.15 ± 4.38
Basal HCO3
 (mmol/L) 25.32 ± 0.25
Intraprocedural pH 7.35 ± 0.06
Intraprocedural PaO2 (mmHg) 128.57 ± 37.81
Intraprocedural PaCO2 (mmHg) 45.57 ± 7.59
Intraprocedural HCO3
 (mmol/L) 24.62 ± 1.92
D pH (basal to intraprocedural,% change) 0.84 ± 0.94
D PaO2 (basal to intraprocedural,% change) 48.01 ± 45.60
D PaCO2 (basal to intraprocedural,% change) 16.80 ± 23.60
D HCO3
 (basal to intraprocedural,% change) 2.76 ± 8.35
Procedural complication, n (%) 26/72 (36)
Major procedural complication*, n (%) 5/26 (19)
Recurrence of AF occurring within 48 h, n (%) 21/72 (29)
ASA: American Society of Anesthesiologists physical status classification
Vital Capacity, NYHA: New York Heart Association. *¼Major procedural c
disability or prolonged hospitalization. Bold values have been used to indDiamond Bar, CA, USA) with image integration using com-
puter tomography or magnetic resonance reconstruction of
the left atrium. Catheter ablation procedure was performed
using radiofrequency energy or cryoablation balloon ablation
catheter (Arctic Front, Medtronic, Minneapolis, MN, USA). The
electroanatomic mapping systems and the energy sources
used during the procedure were selected by the electrophys-
iology team in relation to clinical characteristics of the
patient.Statistical analysis
The normal distribution for continuous variables was
assessed by KolmogoroveSmirnov test. Categorical variables
were represented as percentages, continuous variables as
mean ± standard deviation. Comparisons between groups
were performed by unpaired samples two-sided t-test or chi-
square test, with continuity correction, where appropriate.





62 ± 10 62 ± 10 0.854
33 (81) 25 (79) 0.856
20 (49) 16 (52) 1.000
5 (12) 4 (14) 0.868
18 (44) 14 (45) 0.906
7 (17) 7 (22) 0.102
2 (5) 0 (0) 0.632
39 (95) 31 (100) 0.632
23 (56) 15 (48) 0.492
18 (44) 16 (52) 0.492
81 ± 16 83 ± 15 0.569
173 ± 19 169 ± 24 0.696
27 ± 4 28 ± 4 0.261
56 ± 9 59 ± 6 0.237
4.36 ± 1.29 4.27 ± 1.16 0.767
3.14 ± 0.88 3.25 ± 0.91 0.628
261 ± 42 268 ± 47 0.516
34 (83) 25 (81) 1.000
7 (17) 6 (19) 1.000
164 ± 47 171 ± 56 0.754
156 ± 44 N/A N/A
7.41 ± 0.01 7.42 ± 0.01 0.216
82.89 ± 11.81 87.69 ± 12.97 0.150
40.50 ± 0.85 36.88 ± 0.84 0.008
25.65 ± 0.31 24.68 ± 0.43 0.072
7.37 ± 0.05 7.32 ± 0.05 0.001
117.10 ± 27.25 148.17 ± 45.29 0.004
43.37 ± 6.91 49.33 ± 7.34 0.002
24.71 ± 2.12 24.48 ± 1.53 0.622
0.52 ± 0.83 1.44 ± 0.87 0.002
37.14 ± 30.95 68.29 ± 60.94 0.079
7.21 ± 15.55 34.91 ± 25.76 0.001
3.08 ± 9.76 2.17 ± 4.87 0.684
13/41 (32) 13/31 (42) 0.518
2/13 (15) 3/13 (23) 1.000
11/41 (27) 10/31 (32) 0.810
system, FEV1: forced expiratory volume in the 1st second, FVC: Forced
omplications are those that required intervention, or led to long-term
icate statistically significant variables.
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value less than 0.05 was considered statistically significant.Results
During the study period 72 electrophysiology procedures car-
ried out in deep sedation were evaluated; 41 (57%) procedures
were performed with NIV (NIV group) and the other 31 (43%)
with-out NIV (deep sedation group). The clinical characteris-
tics of the patients and the procedural details are shown in
Table 1.
NIV arm of this study has been described separately else-
where [16].
The two groups of patients showed no differences in these
fields, but between the two groups, a significant variation was
present in the basal PaCO2 (p ¼ 0.008) e with values in the
physiological range e and in intra-procedural blood gas pa-
rameters (pH p ¼ 0.001, PaO2 p ¼ 0.004, PaCO2 p ¼ 0.002
respectively (Fig. 2)).
Analysis of the percentage change between basal to intra-
procedural blood gas parameters (Fig. 3) shows a statistical
variation in the changing of pH and PaCO2 (p¼ 0.002 and 0.001,
respectively).Fig. 2 e Intra-procedural differencesDuring NIV procedures there were no problems due to
mask-related difficulties, gastric distention, NIV discomfort or
significant hemodynamic alterations related to positive pres-
sure ventilation. In the deep sedation procedure there were
two episodes of respiratory complications with severe hy-
percapnia (achieved a PaCO2 greater than 60 mmHg) treated
with application of NIV. Endotracheal intubation was not
necessary in any case.
Adverse events, focused on periprocedural complications,
were reported in 26 patients (36%). Among the complications,
vascular access complications occurred in nine cases (iatro-
genic femoral pseudoaneurysms that required percutaneous
treatment [17] in 5 cases and femoral hematoma with
decrease in hemoglobin levels greater than 2 g/dl in four
cases); none of these cases required transfusion support.
Pleuro-pericardial effusion was documented in 8 cases; exac-
erbation of bronchial asthma in three cases; bradyarrhythmia
requesting definitive pacemaker implantation in two cases;
pulmonary embolism in one case; procedural myocardial
infarction in one case; post-procedural stroke in one case and
permanent paralysis of the phrenic nerve in one case.
The recurrence of AF within 48 h of the electrophysiolog-
ical procedure was recorded in 21 patients (29%) and was
treated by electrical or pharmacological cardioversion.in arterial blood gas variables.
Fig. 3 e Intra-procedural changes in arterial blood gas variables (percentage variation compared to basal values).
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Deep sedation for catheter ablation of AF is feasible and safe
[4] while maintaining spontaneous ventilation. In our seda-
tion procedures in catheter ablation of AF the NIV was safe as
well, and maintained (although with respiratory parameters
in the physiological range) a better homeostasis in these pa-
rameters compared to deep sedation in breathing
spontaneously.
Data shown in Figs. 2 and 3 confirmed a lower impact of
NIV on arterial blood gas tensions and hematic pH balance [18]
compared to deep sedation.
While statistically significant differences were found, the
absolute value differences had a clinically limited benefit;
using NIV made it possible to reduce the flow of oxygen
administered to the patient during the procedure and main-
tain better respiratory dynamics. These conditions allowed us
to maintain effective CO2 elimination with minimum impact
on the pH compared to the deep sedation group.
Furthermore, in the 2 cases of patients who developed
severe hypercapnia during deep sedation, the application of
NIV was effective in solving the respiratory problem withoutthe need for endotracheal intubation. This data shows an
important and clinically relevant difference between the
groups, although the small sample size does not allow
to compare this end point between the two arms of the
study.
Deep sedation requires frequent control and titration by
anesthesiologist due to minor problems such as requiring
high oxygen dose, great difference between basal and intra-
procedural gas properties and occasional hypercapnia. The
NIV is useful to mitigate these problems [6e12]. Furthermore,
NIV allows to reduce the risk of hemodynamic, respiratory or
neurological problems secondary to improper ventilation. We
didn't have problems related to mask-related difficulties,
gastric distention, NIV discomfort or significant hemody-
namic alterations related to positive pressure ventilation.
Also, consideration must be given to the demographic
characteristics of own patients: our population had a high
number of overweight patients (overweight 39%, obese 25%)
and with a history of smoking (44%). In relation to these
conditions, even when outside the guidelines [13,14], our pa-
tients' baseline respiratory function characterization was
performed. This characterization allowed us to exclude pa-
tients with respiratory insufficiency from the study.
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tients evaluated, which did not arrive at the number of pa-
tients evaluated in other studies that assessed the safety of
deep sedation [4] or high-frequency jet ventilation [5].
As previously described, AF catheter ablation procedure
has substantial procedural risks [2,3,19]. Most of the compli-
cations (12/26 cases) that we reported were due to the difficult
balance between bleeding (due to systemic anticoagulation)
and thrombotic (ablation procedure and recurrence of AF)
processes. In our cases we did not report massive effusion or
cardiac tamponade. Pleuro-pericardial effusion is due to the
irritation of the serosa secondary to the ablation procedure as
well as paralysis of the phrenic nerve and the damage
occurring to the conduction system.
Incidence of major procedural complications (5/26 cases)
was comparable to the previous reports [20,21], do not show
differences in the two groups and are imputable to electro-
physiological procedure rather than anesthetic management.
Of theminor complications, the only one related to anesthetic
management was exacerbation of bronchial asthma. We did
not find significant differences between the two anesthetic
regimens tested (two cases in NIV group vs one case in the
deep sedation group). These patients responded rapidly to
treatmentwith inhaled b2-agonists and showed no alterations
in chest X-ray compatible with bronchopneumonia.
Own data on the early recurrence of AF are in line with the
literature, and this event was not related to the long-term
success but was due to edema and inflammation of the
myocardium subjected to ablation [1]. In relation to the
thromboembolic risk of early relapse of AF, international
guidelines [1] recommend oral anticoagulation therapy in the
first few months post-ablation.
In conclusion, our study suggests that in catheter AF
ablation, NIV proved to be a safe practice in anesthesiological
management, as it can treat respiratory depression induced
by sedation and maintain better respiratory homeostasis and
better arterial blood gas balancewhen added to deep sedation.
Furthermore, during the procedure patient safety was also
ensured by a ventilator, which allowed continuous control of
Tidal Volume, amount of ventilation lost to leak and effective
minute ventilation.Funding sources
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